Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Arlo-Cel Delivers High, Durable Responses With Manageable Safety in R/R Myeloma

October 22nd 2025

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

Dr Gupta on Responses With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

October 22nd 2025

Shilpa Gupta, MD, discusses response and subgroup data with enfortumab vedotin plus pembrolizumab in locally advanced/ metastatic urothelial carcinoma.

FDA Accepts NDA for Nilotinib Biosimilar XS003 for Chronic Myeloid Leukemia

October 21st 2025

XS003 shows bioequivalence to nilotinib at half the dose with a reduced food effect for patients with CML.

Liso-Cel Data Confirm Durable Efficacy and Confer Broad Use in R/R LBCL

October 21st 2025

Taylor Brooks, MD, discusses data that supported the FDA approvals of liso-cel across LBCL treatment settings and details of the agent’s toxicity profile.

HLX43 Nets FDA Orphan Drug Designation in Thymic Epithelial Tumors

October 21st 2025

The FDA granted orphan drug designation to HLX43 for thymic epithelial tumors

Long-Term DeFi Data Confirm Durable Efficacy and Consistent Safety of Nirogacestat in Desmoid Tumors

October 21st 2025

Final DeFi trial results show sustained responses, improved PROs, and a stable safety profile with long-term nirogacestat in desmoid tumors.

Bemarituzumab/Chemo Combo Translates to OS Advantage in FGFR2b+ Gastric/GEJ Cancer

October 20th 2025

Bemarituzumab/mFOLFOX6 produced an OS advantage over placebo/mFOLFOX6 in FGFR2b-overexpressing gastric/GEJ cancer; this was attenuated at longer follow-up.

Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease

October 19th 2025

Zipalertinib demonstrated preliminary efficacy and low rates of treatment-related dose reductions and discontinuations in NSCLC harboring EGFR mutations and CNS metastases and/or leptomeningeal disease.

Enfortumab Vedotin Plus Pembrolizumab Shows First-Line Activity in PD-L1+ Recurrent/Metastatic HNSCC

October 19th 2025

Enfortumab vedotin plus pembrolizumab demonstrated meaningful first-line clinical activity in PD-L1–positive recurrent or metastatic HNSCC.

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC

October 19th 2025

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

T-DXd Improves IDFS and DFS vs T-DM1 in HER2+ Breast Cancer With Residual Invasive Disease

October 18th 2025

T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.

Incidence of Second Primary Tumors Is Similar Between Adjuvant Cemiplimab and Placebo in High-Risk CSCC

October 18th 2025

Adjuvant cemiplimab and placebo were associated with similar rates of second primary tumors in high-risk CSCC.

Phase 2 BNT111/Cemiplimab Data Prove Positive in PD-(L)1-Relapsed/Refractory Melanoma

October 18th 2025

BNT111 plus cemiplimab achieved an 18.1% ORR in PD-(L)1–refractory melanoma, meeting its primary end point in the phase 2 BNT111-01 trial.

Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy

October 18th 2025

Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.

Lenvatinib Plus Pembrolizumab and Chemotherapy Fails to Improve OS in Advanced ESCC

October 17th 2025

First-line treatment with lenvatinib, pembrolizumab, and chemotherapy did not improve OS vs chemoimmunotherapy in patients with advanced ESCC.

Adjuvant Cemiplimab Recommended for European Approval in CSCC

October 17th 2025

The EMA’s CHMP has recommended the approval of adjuvant cemiplimab in CSCC at high risk of recurrence after surgery and radiation

Dr Sweis on the Expected Safety Profile of XmAb819 in RCC

October 17th 2025

Randy F. Sweis, MD, discusses potential toxicities and mitigation strategies associated with the bispecific T-cell engager XmAb819.

Dr Elias on the Role of Olaparib Maintenance Therapy For BRCA1/2-Mutated Ovarian Cancer

October 17th 2025

Kevin Elias, MD, discusses the role of olaparib maintenance therapy for patients with BRCA1 and BRCA2-mutated ovarian cancer.

Dr Mahvash on the Clinical Impact of the FDA Approval of SIR-Spheres Y-90 Resin Microspheres for Unresectable HCC

October 16th 2025

Armeen Mahvash, MD, discusses the clinical impact of the FDA approval of SIR-Spheres Y-90 resin microspheres for unresectable hepatocellular carcinoma.

Dr Patel on the FDA Approval of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma

October 16th 2025

Vishal A. Patel, MD, discusses the FDA approval of adjuvant cemiplimab for CSCC at high risk of recurrence following surgery and radiation.